Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydroxyfasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 6/20 | 0.73 |
| ▸ | ROCK1 known ✓ | Q13464 | 5/20 | 0.73 |
| ▸ | PRKCE known ✓ | Q02156 | 3/20 | 0.73 |
| ▸ | PRKCD known ✓ | Q05655 | 3/20 | 0.73 |
| ▸ | PRKD1 known ✓ | Q15139 | 3/20 | 0.73 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.61 |
| ▸ | PRKD3 known ✓ | O94806 | 2/20 | 0.61 |
| ▸ | PRKCG known ✓ | P05129 | 2/20 | 0.61 |
| ▸ | PRKCB known ✓ | P05771 | 2/20 | 0.61 |
| ▸ | PRKCA known ✓ | P17252 | 2/20 | 0.61 |
| ▸ | PRKCH known ✓ | P24723 | 2/20 | 0.61 |
| ▸ | PRKCI known ✓ | P41743 | 2/20 | 0.61 |
| ▸ | PRKCQ known ✓ | Q04759 | 2/20 | 0.61 |
| ▸ | PRKCZ known ✓ | Q05513 | 2/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.61 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.61 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.61 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyfasudil SCHEMBL30198128 | 1.00 | ROCK2 (0.73) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Hydroxyfasudil SCHEMBL31717522 | 0.99 | ROCK2 (0.72) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Hydroxyfasudil SCHEMBL1827528 | 0.99 | ROCK2 (0.75) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Hydroxyfasudil SCHEMBL29473349 | 0.99 | ROCK2 (0.75) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Hydroxyfasudil SCHEMBL30309462 | 0.99 | ROCK2 (0.75) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| SCHEMBL2907389 | 0.94 | ROCK2 (0.67) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| SCHEMBL9617966 | 0.86 | SMN1; SMN2 (0.67) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| SCHEMBL13513878 | 0.86 | ROCK2 (0.77) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| SCHEMBL6845278 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| SCHEMBL2908958 | 0.85 | ROCK2 (0.75) | ROCK2ROCK1PRKCEPRKCDPRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110223177-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2011-09-15 | — | — | US | claimed |
| EP-2323637-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | University of East Anglia (GB) | 2011-05-25 | — | — | EP | claimed |
| WO-2010029350-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2010-03-18 | — | — | WO | claimed |
| US-20110223177-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2011-09-15 | — | — | US | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |